

Elbasvir-Grazoprevir in HCV and HIV Coinfection, GT 1, 4, or 6 C-EDGE CO-INFECTION

Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4, or 6

C-EDGE CO-INFECTION: Study Features

- **Design:** Prospective, open-label, single-arm study examining the safety and efficacy of a fixed-dose combination of elbasvir-grazoprevir for 12 weeks in treatment-naïve patients with chronic HCV genotype 1, 4, or 6 and HIV coinfection.
- **Entry Criteria**
 - Chronic HCV Genotype 1, 4, or 6
 - Age 18 years or older
 - HCV RNA $\geq 10,000$ IU/mL
 - No prior treatment
 - Compensated cirrhosis permitted
 - HIV infection
- **Primary End-Point:** SVR12

Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4, or 6 C-EDGE CO-INFECTION: Study Design

Week 0 4 8 12 16 20 24 28

HIV-HCV Coinfected
Treatment-naïve
GT 1, 4, or 6

n = 218

Elbasvir-Grazoprevir

SVR12

Drug Dosing

Elbasvir-grazoprevir (50/100 mg): fixed dose combination; one pill once daily

Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4, or 6

C-EDGE CO-INFECTION: Participants

Baseline Characteristic	Elbasvir-Grazoprevir (n = 218)
Age, mean	49
Male, n (%)	183 (84%)
Race, n (%)	
White	167 (77%)
Black or African-American	38 (17%)
Other	13 (6%)
HCV genotype, n (%)	
1a	144 (66%)
1b	44 (20%)
4	28 (13%)
6	2 (1%)
Fibrosis stage, n (%)	
F0-2	160 (73%)
F3	23 (11%)
F4	35 (16%)
Mean baseline HCV RNA, log ₁₀ IU/ml	6.03

Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4, or 6 C-EDGE CO-INFECTION: Participants


HIV Characteristics	Elbasvir-Grazoprevir (n = 218)
Median CD4 cell count, (IQR)	568 (424-766)
ART Status	
On ART with undetectable HIV RNA	211 (97%)
ART naïve	7 (3%)
ART nucleos(t)ide pair	
Abacavir-containing	47 (22%)
Tenofovir-containing	164 (75%)
None	7 (3%)
ART Third Agent	
Raltegravir	113 (52%)
Dolutegravir	59 (27%)
Rilpivirine	38 (17%)
None	8 (4%)
IQR = interquartile range; ART = antiretroviral therapy	

Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4, or 6

C-EDGE CO-INFECTION: Results

C-EDGE CO-INFECTION: SVR12 Results by Genotype



Overall SVR12 results includes the 2 patients with GT 6, who both achieved SVR12.

Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4, or 6 C-EDGE CO-INFECTION: Adverse Events

Adverse Event (AE), n (%)	Elbasvir-Grazoprevir (n = 218)	
Discontinuation due to AE	0	
Serious AEs	2 (1%)	
Deaths	0	
Any AE in >5% of patients		
Fatigue	29 (13%)	
Headache	27 (12%)	
Nausea	20 (9%)	
Upper respiratory tract infection	18 (8%)	
Diarrhea	16 (7%)	
Insomnia	15 (7%)	
Grade 3 or 4 laboratory abnormality	<u>Grade 3</u>	<u>Grade 4</u>
Total bilirubin	1 (<1%)	0
ALT elevation	3 (1%)	2 (1%)
AST elevation	0	1 (<1%)
Hemoglobin	0	0

Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4, or 6 C-EDGE CO-INFECTION: Conclusions

Conclusions: “This HCV treatment regimen seems to be effective and well tolerated for patients co-infected with HIV with or without cirrhosis. These data are consistent with previous trials of this regimen in the monoinfected population. This regimen continues to be studied in phase 3 trials.”

Acknowledgments

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.



The content in this presentation is that of the author(s) and does not necessarily represent the official position of views of, nor an endorsement, by the Centers for Disease Control and Prevention.